Pharma deals prompt ownership questions
New deals between big pharma and academic institutions raise questions about IP ownership and patent strategies. Zöe Clyde-Watson examines how to avoid entitlement disputes
A number of reports have recently appeared about large pharmaceutical companies looking beyond their own walls for scientific discoveries by partnering with academic institutions and in new ways, significantly different from old-style partnering arrangements....
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.